


AMENDMENTS TO THE ABSTRACT

Please substitute the following paragraph for the abstract now appearing in the currently filed specification:

REPLACEMENT ABSTRACT

The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivatives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action. Specifically, the present invention the metastin derivative (I), which is represented by formula:



[wherein, Z¹, Z³, Z⁵ and Z⁷ represent H or a C₁₋₃ alkyl group; Z², Z⁴, Z⁶ and Z⁸ represent H, O or S; R¹ represents (1) H, or (2) a C₁₋₈ alkyl group optionally substituted with a substituent selected from the group consisting of a carbamoyl group, a hydroxyl group and a aromatic cyclic group; R² represents (1) H or (2) a cyclic or linear C₁₋₁₀ alkyl group, or (3) a C₁₋₁₀ alkyl group consisting of a cyclic alkyl group and a linear alkyl group; R³ represents a C₁₋₈ alkyl group having a basic group, an aralkyl group having a basic group, a C₁₋₄ alkyl group having a non-aromatic cyclic hydrocarbon group of carbon atoms not greater than 7 having a basic group, or a C₁₋₄ alkyl group having a non-aromatic heterocyclic group of carbon atoms not greater than 7 having a basic group; R⁴ represents a C₁₋₄ alkyl group, which may optionally be substituted with a substituent selected from the group consisting of a C₆₋₁₂ aromatic hydrocarbon group, an aromatic heterocyclic group, a C₈₋₁₄ aromatic fused ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group, and a non-aromatic heterocyclic group having carbon atoms not greater than 7; X represents a group shown by formula: NHCH(Q¹)YQ²C(=Z⁹) (wherein, Q¹ represents a C₁₋₄ alkyl group, which may optionally be substituted with a substituent selected from the group consisting of an aromatic hydrocarbon group, an aromatic heterocyclic group, a C₈₋₁₄ aromatic fused ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group having carbon atoms not greater than 7, and a non-aromatic heterocyclic group having carbon atoms not greater than 7; Q² represents CH₂, NH or O; Y represents CONH, CSNH, CH₂NH, NHCO, CH₂O, CH₂S or CH₂CH₂; Z⁹ represents H, O or S); and P represents (1) H; (2) an optional amino acid residue continuously or discontinuously bound from the C-terminal end of the 1-48 amino acid sequence in the amino acid sequence represented by SEQ ID NO: 1; (3) a group represented by formula: J¹-J²-C(J³)(Q³)Y¹C(J⁴)(Q⁴)Y²C(J⁵)(Q⁵)Y³C(J⁶)(Q⁶)C(=Z¹⁰) (wherein, J¹ represents (a) H or (b) (i) a C₁₋₁₅ acyl group, (ii) a C₁₋₁₅ alkyl group, (iii) a carbamoyl group, (iv) a C₁₋₁₅ alkylcarbamoyl group, (v) a C₁₋₁₅ alkanoylcarbamoyl group, (vi) an aminocarbamoyl group, (vii) a C₁₋₁₅ alkylaminocarbamoyl group, (viii) an oxy carbonyl group, (ix) a C₁₋₁₅ alkoxy carbonyl group, (x) a sulfonyl group, (xi) an amidino group, (xii) a C₁₋₁₅ alkylamidino group, (xiii) a C₁₋₁₅ acylamidino group, (xiv) a C₁₋₁₅ alkylsulfonyl group, or (xv) a oxaryl group, which group may optionally be substituted with cyclic group; J² represents NH, CH₂, O or S; J³ through J⁶ represent H or a C₁₋₃ alkyl group; Q³ through Q⁶ represent a C₁₋₄ alkyl group, which may

optionally be substituted with a substituent selected from the group consisting of a C₆₋₁₂ aromatic hydrocarbon group, an aromatic heterocyclic group, a C₈₋₁₄ aromatic fused ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group having carbon atoms not greater than 7, a non-aromatic heterocyclic group having carbon atoms not greater than 7, an amino group, a guanidino group, a hydroxyl group, a carboxyl group, a carbamoyl group, and a sulphydryl group, or H; J³ and Q³, J⁴ and Q⁴, J⁵ and Q⁵ or J⁶ and Q⁶ may be combined together, or, J¹ and Q³, Y¹ and Q⁴, Y² and Q⁵, or Y³ and Q⁶ may be combined together, to form a ring; Y¹ through Y³ represent a group represented by formula: CON(J¹³), CSN(J¹³), C(J¹⁴)N(J¹³) or N(J¹³)CO (wherein J¹³ and J¹⁴ represent H or a C₁₋₃-alkyl group); and Z¹⁰ represents H, O or S); (4) a group represented by formula: J¹-J²-C(J⁷)(Q⁷)Y²C(J⁸)(Q⁸)Y³C(J⁹)(Q⁹)C(-Z¹⁰) (wherein, J¹ and J² have the same significance as described above; J⁷ through J⁹ have the same significance as J³; Q⁷ through Q⁹ have the same significance as Q³; Y² and Y³ have the same significance as described above; Z¹⁰ has the same significance as described above; J⁷ and Q⁷, J⁸ and Q⁸ or J⁹ and Q⁹ may be combined together, or, J² and Q⁷, Y² and Q⁸ or Y³ and Q⁹ may be combined together, to form a ring); (5) a group represented by formula: J¹-J²-C(J¹⁰)(Q¹⁰)Y³C(J¹¹)(Q¹¹)C(-Z¹⁰) (wherein, J¹ and J² have the same significance as described above represents; J¹⁰ and J¹¹ have the same significance as J³; Q¹⁰ and Q¹¹ have the same significance as Q³; Y³ has the same significance as described above; Z¹⁰ has the same significance as described above; and J¹⁰ and Q¹⁰ or J¹¹ and Q¹¹ may be combined together, or J² and Q¹⁰ or Y³ and Q¹¹ may be combined together, to form a ring); (6) a group represented by formula: J¹-J²-C(J¹²)(Q¹²)C(-Z¹⁰) (wherein, J¹ and J² have the same significance as described above; J¹² has the same significance as J³; Q¹² has the same significance as Q³; Z¹⁰ has the same significance as described above; and J¹² and Q¹² may be combined together, or J² and Q¹² may be combined together, to form a ring); or (7) a group represented by formula: J¹- (wherein, J¹ has the same significance as described above)], or a salt thereof.